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Abstract 
Objective: To study knowledge regarding genitourinary syndrome of menopause (GSM) and the treatments for it 
and to analyze treatment adherence during the COVID-19 confinement.
Methods: Multi-center observational study including women between 35 and 75 years. An extension study of treat-
ment adherence was conducted during the coronavirus pandemic between March and April 2020.
Results: A sample of 2355 women were included. Vaginal dryness was the most frequently identified symptom 
(74.3%). Lubricants were the best-known treatments (69.6%), followed by local estrogens (25.7%); 66% of the women 
did not speak to their gynecologist about sexuality. Comparative analyses were conducted according to age, meno-
pausal status, type of menopause, place of residence, type of health care received and level of education. During the 
coronavirus confinement period, adherence to treatments for vulvovaginal atrophy was poor in 72.5% asked (n = 204). 
Reduced sexual activity (p > 0.001) and coronavirus diagnosis (p = 0.003) were significantly associated with poorer 
treatment compliance.
Conclusions: There is great lack of knowledge of the treatments used for GSM. Most women do not talk to their 
gynecologist about sexuality. Adherence to treatments during the coronavirus confinement has been worryingly low.
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Background
Genitourinary syndrome of menopause (GSM) is one of 
the most frequent complaints referred in transition and 
postmenopause and it could impact on the quality of life 
and sexual function of women [1]. Although sexuality is 
an important element of the lives of many midlife women 
[2], only a very small percentage of midlife women report 
having discussed their sexual problems with a healthcare 
professional [3].
If women are aware of the genital changes produced by 
hormonal decline and how this can affect their sexuality, 
it would be easier to identify women with dysfunction or 
possible symptoms that require treatment. There is an 
increasing tendency among clinicians to share the treat-
ment options for vulvovaginal atrophy with the patient. 
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The term "empowered therapy" has even been introduced 
in some publications [4–6]. To make an informed choice, 
it is important that women have good knowledge about 
GSM that is free of myths and false beliefs.
This study is part of a population survey known as the 
COMEM (“COnocimiento de las Mujeres Españolas en 
Menopausia” in Spanish) study. Data related to meno-
pausal treatments have already been partially published 
elsewhere [7]. The GSM-related study had two objec-
tives: first, to determine what women know about GSM. 
Second, considering a small sample of women who pre-
viously answered the survey, we aimed to evaluate the 
adherence to treatment for GSM during the period of 
confinement that was imposed due to the coronavirus 
pandemic (COVID-19).
Methods
This was a multi-center cross-sectional observational 
study carried out between January and June 2019, using 
a sample of 2500 women aged between 35 and 75 years. 
They participants were asked to complete an anony-
mous and voluntary survey written in simple and clear 
language.
A team of seven menopause experts selected questions 
structured in several clinical domains. The study related 
to therapies in menopause and socio-demographic char-
acteristics of the sample the have been published previ-
ously [7]. In the present study, we included the same 
cohort of women (n = 2355).
The questionnaire was offered to all women in the 
gynecology consulting-rooms of the participating cent-
ers, either they were patients or companions. Women 
who with physical, psychological or language incapacity 
to understand the survey questions, or those who did not 
want to participate were excluded from the study.
In the extension phase of the adherence study, women 
with treatment for GSM who had done the survey pre-
viously, were asked about the adherence and attitude to 
treatment during the state of alarm for coronavirus infec-
tion in Spain (from March 14 to June 21, 2020). Women 
who discontinued treatment before that time were not 
included in the extension phase. They were contacted by 
phone at the control visit after indicating treatment for 
GSM. Epidemiological data, sexual activity during con-
finement, type of treatment, dosage, and coronavirus 
infection data were collected. We evaluated adherence to 
pharmacological treatment using the Morisky–Green–
Levine questionnaire with four items: each item has a 
dichotomous answer: ’yes’ or ’no’. The questions ask if the 
patient takes the medicine correctly, if she has forgot-
ten and if she abandons it in certain circumstances. The 
total score ranges from 0 to 4 points. A score of 4 points 
indicates good adherence to treatment, whilst less than 4 
points indicates poor adherence [8].
The research was conducted in accordance with Good 
Clinical Practice standards and the current revision of 
the Declaration of Helsinki. The study was approved by 
the Research Ethics Committee of Aragon Spain (C.I. 
PI18/374) and of each involved center and was included 
in the Spanish Menopause Society National Research 
Network (REIM).
Statistical analysis
Categorical variables were reported in frequencies and 
percentages. Quantitative variables were showed using 
mean and standard deviation. Chi-Square test/Fisher’s 
exact test or Student’s T-test were used for each ques-
tion of the questionnaire. The Mann–Whitney U test was 
used for the analysis of dichotomous variables and the 
Kruskal–Wallis test for non-dichotomous variables when 
the distribution was non-parametric. The statistically sig-
nificance was considered as p value < 0.05.
Data was collected and codified using IBM Statistics 
Process Social Sciences 22.0 for Windows (Copyright© 
SPSS Inc., 2013) for subsequent statistical analysis.
Results
The answers obtained to the questions of the question-
naire are shown in Table 1. Vaginal dryness was a symp-
tom identified with menopause by 74.3% of the women 
surveyed and decreased sexual desire by 44.8%. Sexual 
dysfunction was recognized as a disease associated with 
menopause by 29%. When asked how menopause affects 
sexuality, 65% answered that menopause decreases sexual 
desire. Pain with sexual activity and decreased frequency 
of sexual intercourse were identify by 34.9% and 27.4% 
of women asked respectively. Urinary incontinence was 
associated with menopause by 54% of the women sur-
veyed, while urinary infections in 10.6%.
Among the women surveyed, the most widely known 
treatments for GSM were lubricants (69.6%) followed by 
local estrogens (25.7%), whilst 18.8% of the women did 
not know of any treatment. The benefit of maintaining 
sexual activity for vaginal atrophy was recognized by 15% 
of women. A total of 66% of the women surveyed had not 
discussed the issue of sexuality with their gynecologist, 
and for most of these women (57.1%) this was because 
their gynecologist had never asked them (Table 1).
During the coronavirus confinement period, 204 
women with treatment for GSM were asked; The median 
age was 58 years (IQR 54–60) and the age of menopause 
50  years (IQR 49–52). The demographic characteristics 
of the adherence extension phase and the treatments 
indicated for GSM in the year prior to the declaration of 
the state of alarm are shown in Table 2. Poor compliance 
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with treatment was observed in 72.5% of the patients 
included in the study. The most frequent causes of poor 
adherence were omission (67.7%) and changes in sexual 
Table 1 GSM knowledge survey and responses given by women 
surveyed
DK Don’t know
n % of total 
respondents 
(n = 2355) (%)
Which symptoms are associated with meno-
pause?
None 14 0.6
Decreased sexual desire 1054 44.8
Vaginal dryness 1749 74.3
Pain during intercourse 822 34.9
Vaginal itchiness 298 12.6
Vulvar itchiness 876 37.2
DK 28 1.2
Which conditions are associated with meno-
pause?
None 99 4.2
Sexual dysfunction 682 29.0
Vaginal atrophy 1766 75.0
Urinary infections 250 10.6
Urinary incontinence 1272 54
DK 88 3.7
How does menopause affect sexuality?
No effects 306 13.0
Decreased sexual desire 1530 65.0
Decreased frequency of sexual activity 646 27.4
DK 186 7.9
Which of these treatments do you know of for 
improving vaginal atrophy?
Vaginal lubricants 1640 69.6
Vibrators 108 4.6
Laser therapy 73 3.1
Hydrating Creams 558 23.7
Estrogen creams 605 25.7
Sexual intercourse 353 15.0
Hyaluronic acid 172 7.3
DK 443 18.8




If no, indicate the reason(s)
Mistrust 49 2.1
Embarrassment 254 10.8
He/she has never asked me 893 57.1
Lack of consultation time 286 18.2
I do not attend this type of clinic 374 24.0
I do not think it is important to him/her 214 9.1
Table 2 Clinical and demographic characteristics of the sample 
analyzed in the extension study of GSM treatment adherence 
during COVID-19 confinement
MTH Menopause hormone therapy
* IQR: Interquartile range
a Questions included in the Morinsky–Green–Levine test [8]
b Compliance was considered to be good if the 4 questions were answered as 
follows: No/Yes/No/No
n (%) (n = 204)
Age
Median (IQR*) 58 (54–60)
Years of menopause












Lubricants, moisturizers 48 (23.5)





Do you ever forget to take your medication? 52 (25.5)
Do you take the medication at the prescribed times? 96 (47.1)
If you feel well, do you not take it? 52 (25.5)




Reasons for poor compliance
Omission 132 (66.7)
Changes in sexual activity 100 (49)
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activity (49%). Less sexual activity during the state of 
alarm and having been diagnosed with coronavirus infec-
tion (11.8% of the women in the study) were significantly 
associated with poorer treatment compliance (p < 0.001, 
p = 0.003 respectively) (Table 3).
Discussion
The main finding of this survey is that the sample of 
women analyzed have poor knowledge about GSM, 
particularly about treatment options. In addition, there 
is also a clear lack of communication between women 
and their gynecologist in relation to the issue of sexu-
ality. To date, this is the largest sample of women to 
have been surveyed about their beliefs and knowledge 
regarding GSM, its treatments, and associated sexuality 
issues in Spain. In addition, during the extension phase, 
we have verified that adherence to GSM treatments 
has been remarkably poor during the coronavirus 
confinement period. To our knowledge, this is the first 
study to assess compliance with treatment for GSM 
during the coronavirus pandemic.
Several studies have analyzed the prevalence and 
impact of vulvo-vaginal atrophy (VVA) symptoms 
experienced during menopause [9–12]. The most com-
mon symptom among all of these is vaginal dryness, 
with the European EVES study reporting an estimated 
prevalence of up to 90%. Dyspareunia is less prevalent 
(44–72%) but is the most bothersome symptom [9, 10, 
12]. Sexuality is the most affected area, as indicated by 
the VIVA (65%) [11], and the American REVIVE (59%) 
surveys [9]. In the CLOSER study, the reduction of 
sexual satisfaction and dyspareunia are causes of sig-
nificant sexual dysfunction [13]. However, in some of 
these studies, vaginal atrophy was not recognized as a 
medical condition by several women, who felt that their 
concerns had been dismissed as a normal part of aging 
[9, 10, 14].
When asked about the conditions or symptoms associ-
ated with menopause, most of the women in our survey 
identified vaginal dryness (74.3%); whilst other condi-
tions such as decreased desire or sexual dysfunction were 
less recognized (44.8% and 29% respectively). The atti-
tudes of the women towards their symptoms are highly 
variable and may depend on sociocultural and even per-
sonality factors [8, 9, 13]. For instance, according to the 
REVIVE surveys [9, 10], women in Europe appear to be 
more aware of the fact that vaginal dryness and dyspare-
unia are menopausal symptoms (53%) than women in the 
USA (38%).
All these survey-based studies included postmeno-
pausal women, most of them over 45  years of age. The 
responses of these women about GSM may be condi-
tioned by their own experience and the presence of vul-
vovaginal symptoms. For this reason, we have thought 
it interesting to also include younger premenopausal 
women. This is a new aspect in this type of study, and 
we think that it better reflects the objective of the study, 
which is to assess women’s knowledge of GSM regardless 
of their experience.
Another factor that could be associated with the per-
ception of VVA symptoms is communication with the 
clinicians and the attitude of women in relation to rais-
ing the issue of GSM, that is, whether they discuss the 
symptoms with their health care practitioner during their 
gynecological appointments. When we specifically asked 
about sexuality in menopause, only a limited number of 
women believed that menopause does not affect sexual-
ity (13%). The majority (65%) thought that menopause 
decreased sexual desire and almost half (34.9%) recog-
nized the symptom of pain during sexual intercourse. 
According to the AGATA study, 78.7% of 913 patients 
Table 3 Factors related to GSM treatment adherence during 
COVID-19 confinement
MTH menopause hormone therapy
* RIQ: Interquartile range
a Compliance was considered to be good if the 4 questions of the Morinsky–
Green–Levine test were answered correctly, as follows: No/Yes/No/No [8]










Median (RIQ*) 58 (53.7–60.2) 59 (54–60) 0.988
Years of menopause
Median (RIQ) 50 (49–52) 50 (49–52) 0.693
Sexually active before confine-
ment
Yes 48 (85.7) 128 (86.5) 0.919
No 8 (14.3) 20 (13.5)
Level of education
Basic-medium 28 (50) 84 (56.8) 0.541
Higher 28 (50) 64 (43.2)
Decreased sexual activity
Yes 12 (21.4) 100 (67.6) < 0.001
No 44 (78.6) 48 (32.4)
Indicated treatments
Lubricants, moisturizers 12 (21.4) 36 (24.3) 0.218
Local estrogens 32 (57.1) 88 (59.5)
Prasterone 4 (7.1) 16 (10.8)
Ospemifene 8 (14.3) 4 (2.7)
MHT - 4 (2,7)
COVID infection
Yes 16 (28.6) 8 (5.4) 0.003
No 40 (71.4) 140 (94.6)
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with VVA had never been questioned by a health care 
practitioner [15].
In accordance with our findings, the Women’s 
EMPOWER survey, an internet-based survey of US 
women with VVA symptoms [4], reported that most 
women were aware of over-the-counter treatments (vagi-
nal lubricants or moisturizers) but knew rather less about 
options such as local estrogen treatments. Other surveys 
evaluated the knowledge, behavior, and attitudes associ-
ated with GSM; the authors valued treatments women 
receive, their satisfaction and concerns, but the treat-
ment options that women are aware of are not discussed 
in depth [9, 10, 15–17]. This is an important aspect to 
consider if patients are to choose the most appropriate 
treatment according to their preferences. It is clear that 
as gynecologists we must improve the information that 
we provide to our patients in this regard.
The issue of communication with the clinician in rela-
tion to sexuality is particularly interesting. Most of the 
women in our sample (66.4%) reported that they did 
not discuss the topic of sexuality with their gynecolo-
gist, the reason for which, according to most women 
(57.1%), was that their clinician had never asked them. In 
accord with this finding, other studies have shown that 
women expect their gynecologist to begin the conversa-
tion in this regard, and that these women have a strong 
desire to obtain accurate medical information about 
VVA [4]. A study was conducted in Spain to evaluate 
whether actively addressing sexuality in a gynecological 
consultation with postmenopausal patients improves the 
diagnosis of sexual problems [18]. A total of 256 post-
menopausal women participated in the study. Of these, 
12.1% reported a sexual problem during the first 5  min 
of the interview. The prevalence of patients with a sexual 
problem increased by 35.9% (from 12.1 to 48.0%) when 
they were asked about sexuality after 5 min (p < 0.0001). 
These findings suggest that gynecologists should reflect 
on this issue and consider asking all menopausal women 
about sexuality.
The clinical efficacy of a treatment over time varies 
depending on persistence and compliance. Lack of adher-
ence to treatment in chronic diseases is a major problem 
worldwide [19]. In GSM, both adherence and persistence 
are low. Among women with GSM who participated in 
the REVIVE study in Spain, 40% reported having dis-
continued treatment for GSM [20]. However, our data 
are even more discouraging. To date, no other study has 
assessed adherence to GSM treatments during the cur-
rent coronavirus pandemic. These novel findings should 
encourage clinicians to reflect on the importance of 
motivating their patients and emphasizing the benefits of 
good treatment compliance to avoid unfavorable clinical 
and economic consequences.
One limitation of our study was the possible selection 
bias. To minimize this source of bias, the size of the 
sample was increased and participation in the survey 
was offered to all women regardless of the reason for 
their medical visit. Nonetheless, we must assume that 
the obtained conclusions cannot be extrapolated to the 
general population and are instead limited to the sam-
ple included in the study. Nonetheless, this work might 
be considered a useful exploratory study that could 
form the basis for future investigations in the general 
population. Another possible limitation of our study is 
related to the choice of questionnaire. There are cur-
rently no questionnaires in Spanish that have been suf-
ficiently recognized and validated as an instrument for 
measuring women’s knowledge of menopause. Finally, 
conducting the Morisky–Green–Levine questionnaire 
by telephone (which was deemed necessary due to the 
confinement situation) could also be viewed as a limita-
tion, since the obtained data may be rather different to 
those that would have been yielded by a self-adminis-
tered test.
Conclusions
There is a considerable lack of knowledge regarding the 
treatments used for GSM. Moreover, most women do not 
talk to their gynecologist about sexuality issues. Adher-
ence to GSM treatments during the coronavirus confine-
ment has been remarkably low. It is therefore of crucial 
importance to implement educational and motivational 
programs and to improve clinician-patient communica-
tion about GSM and sexuality during menopause.
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